Novartis Oncology Offers US Healthcare Professionals Access to ASCO Online Library
US HCPs will be able to choose one Virtual Meeting Track organized by tumor type
Oct 21, 2016
For US oncology healthcare professionals who did not attend the American Society of Clinical Oncology’s (ASCO®) 2016 Annual Meeting, Novartis Oncology is pleased to invite them to virtually attend sessions from one disease track. The theme for ASCO 2016 was “Collective Wisdom: The Future of Patient-Centered Care and Research.” We are excited to offer access through the end of 2016, which includes the Oral Abstract Sessions, Poster Discussion Sessions, Clinical Science Symposia and Educational Sessions, to disease tracks on:
Central Nervous System Tumors
Gastrointestinal (Colorectal) Cancer
Gastrointestinal (Noncolorectal) Cancer
Genitourinary (Nonprostate) Cancer
Genitourinary (Prostate) Cancer
Head and Neck Cancer
Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Hematologic Malignancies – Plasma Cell Dyscrasia
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
This offering is intended to support the scientific exchange of information by providing US healthcare professionals with online access to video-captured sessions from ASCO's 2016 Annual Meeting. Through the https://www.asco2016.com site, US healthcare professionals will be provided access to one Virtual Meeting Track organized by tumor type.
Each Virtual Meeting Track contains unedited, unmodified, and unaltered material from educational sessions and science sessions as presented at ASCO’s 2016 Annual Meeting. As such, the material may contain information about compounds that are either investigational or being studied for new uses whereby efficacy and safety have not been established. Novartis assumes no responsibility for the content contained on the site and there is no guarantee that any compound will become commercially available for the uses under investigation.
While access to one Virtual Meeting Track via the site is provided at no cost, a $99 transfer of value will be reported by Novartis to meet its legally required reporting obligations.
We hope US healthcare professionals will partake in this exciting offering to learn about the data presented at this year’s ASCO Annual Meeting.
Please note that eligibility may be restricted based on employer, committee affiliations or state law.
ASCO® is a registered trademark of the American Society of Clinical Oncology.